Evidence map›Paper›PMID 24320160›Full record

ArticleACS chemical biology2014

Profiling substrates of protein arginine N-methyltransferase 3 with S-adenosyl-L-methionine analogues.

Han Guo, Rui Wang, Weihong Zheng, Yuling Chen, Gil Blum, Haiteng Deng, Minkui Luo

Abstract read
In one paragraph

Article in ACS chemical biology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 49 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. DNA Labeling Using DNA Methyltransferases.Advances in experimental medicine and biology · 2022
    Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Chemical science · 2019
    Article
  12. Article
  13. Article
  14. Mechanisms and Inhibitors of Histone Arginine Methylation.Chemical record (New York, N.Y.) · 2018
    Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Han GuoMolecular Pharmacology and Chemistry Program and ‡Tri-Institutional Training Program in Chemical Biology, Memorial Sloan-Kettering Cancer Center , New York, New York 10065, United States.
Rui Wang
Weihong Zheng
Yuling Chen
Gil Blum
Haiteng Deng
Minkui Luo
Tsinghua University · CNCornell University · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Profile substrates and inhibitors of protein lysine methyltransferaseR01GM096056 · NIGMS · SLOAN-KETTERING INST CAN RESEARCH · PI LUO, MINKUI · 2011 to 2018
$3.2M
Enzyme-engineering Approaches to Dissect Protein Methylation ProfilesDP2OD007335 · OD · SLOAN-KETTERING INST CAN RESEARCH · PI LUO, MINKUI · 2010 to 2010
$2.9M
NCI NIH HHS P30 CA008748NIGMS NIH HHS 1R01GM096056NIGMS NIH HHS R01 GM096056NIH HHS 1DP2-OD007335NIH HHS DP2 OD007335
6 · The paper itself

Abstract

Protein arginine N-methyltransferase 3 (PRMT3) belongs to the family of type I PRMTs and harbors the activity to use S-adenosyl-l-methionine (SAM) as a methyl-donor cofactor for protein arginine labeling. However, PRMT3's functions remain elusive with the lacked knowledge of its target scope in cellular settings. Inspired by the emerging Bioorthogonal Profiling of Protein Methylation (BPPM) using engineered methyltransferases and SAM analogues for target identification, the current work documents the endeavor to systematically explore the SAM-binding pocket of PRMT3 and identify suitable PRMT3 variants for BPPM. The M233G single point mutation transforms PRMT3 into a promiscuous alkyltransferase using sp(2)-β-sulfonium-containing SAM analogues as cofactor surrogates. Here the conserved methionine was defined as a hot spot that can be engineered alone or in combination with nearby residues to render cofactor promiscuity of multiple type I PRMTs. With this promiscuous variant and the matched 4-propargyloxy-but-2-enyl (Pob)-SAM analogue as the BPPM reagents, more than 80 novel proteins were readily uncovered as potential targets of PRMT3 in the cellular context. Subsequent target validation and functional analysis correlated the PRMT3 methylation to several biological processes such as cytoskeleton dynamics, whose roles might be compensated by other PRMTs. These BPPM-revealed substrates are primarily localized but not restricted in cytoplasm, the preferred site of PRMT3. The broad localization pattern may implicate the diverse roles of PRMT3 in the cellular setting. The revelation of PRMT3 targets and the transformative character of BPPM for other PRMTs present unprecedented pathways toward elucidating physiological and pathological roles of diverse PRMTs.

Indexed as

Amino Acid SequenceBinding SitesHumansMethylationModels, MolecularMolecular Sequence DataMutagenesisMutationProtein-Arginine N-MethyltransferasesS-AdenosylmethionineSequence AlignmentSubstrate SpecificityPRMT3 protein, humanProtein-Arginine N-MethyltransferasesS-Adenosylmethionine

Identifiers

PMID24320160
PMCPMC3944066
OpenAlexW2087178700

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.